Marshall Mazepa

Assistant Professor, Medicine - Hematology, Oncology, Transplant

Emailmmazepa@umn.edu

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Expertise related to UN SDGs

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

Fingerprint

The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

6 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

3 Finished
6 Active

Acquired Thrombotic Thrombocytopenic Purpura and Neuropsychologic Complications
Mazepa, M.
ANSWERING TTP FOUNDATION
9/30/19 → 9/29/21
Project: Research project
A Phase 2, multicenter, randomized, placebo-controlled, doubleblind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to stand
Datta, Y. H. & Mazepa, M.
Baxalta US Inc.
7/1/19 → 7/30/24
Project: Research project
HEM-POWR: Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog alfa pegol in Previously Treated Patients with Hemophilia A
Beckman, J. D. & Mazepa, M.
BAYER HEALTHCARE PHARMACEUTICALS
6/17/19 → 6/30/24
Project: Research project
Bayer 20414: A multicenter, non-randomized, open-label, multiple dose escalation study to evaluate thesafety and tolerability of subcutaneous BAY 1093884 in males with hemophilia
Mazepa, M.
BAYER HEALTHCARE PHARMACEUTICALS
3/11/19 → 3/30/24
Project: Research project
A Phase 2, Open-Label Study of INCB050465 in Participants WithAutoimmune Hemolytic Anemia
Vercellotti, G. M. & Mazepa, M.
Incyte Corporation
1/10/19 → 4/30/24
Project: Research project

19 Article
4 Letter
3 Review article
1 Chapter
More
- 1 Conference contribution

A fiery pivot
Cole Pueringer, R., Mazepa, M., Olson, A. P. J. & Ives, S. T., Jul 1 2020, In: Journal of hospital medicine. 15, 7, p. 419-423 5 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Heparin-induced thrombocytopenia associated with collection of hematopoietic progenitor cells by apheresis
Raval, J. S., Park, Y. A., Perjar, I., Mazepa, M. A., Vincent, B. G., Ma, A. D. & Rollins-Raval, M. A., Jan 1 2020, In: Journal of clinical apheresis. 35, 1, p. 59-61 3 p.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
Heterogeneity of diagnosis, treatment, and management for immune thrombotic thrombocytopenic purpura: Are we still peering through the looking glass?
Raval, J. S., Rollins-Raval, M. A., Mazepa, M. A. & Park, Y. A., Jun 1 2020, In: Journal of clinical apheresis. 35, 3, p. 236-237 2 p.
Research output: Contribution to journal › Letter › peer-review
Opioid exposure in haemophilia patients is common and underreported
Peltier, S. J., Mazepa, M. A., Freese, R. L., Nelson, S. F., Kearney, S. L. & Reding, M. T., Mar 2020, In: Haemophilia. 26, 2, p. 251-256 6 p.
Research output: Contribution to journal › Article › peer-review
The Impact of an Undergraduate Biology Class on Donor Recruitment at a Hospital-Based Blood Donor Center
Peedin, A. R., Park, Y. A., Mazepa, M. A., Siniard, R. C., Neish, T. & Raval, J. S., Feb 8 2020, In: American journal of clinical pathology. 153, 3, p. 368-373 6 p.
Research output: Contribution to journal › Article › peer-review